logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis : clinical consequences.

    Article - En anglais

    Background/Aim 

    Norfloxacin prophylaxis decreases the incidence of bacterial infections in high-risk cirrhotic patients, but may promote the development of quinolone-resistant gram-negative bacteria in stools, and eventually lead to infections due to these bacteria.

    The aim of the study was to evaluate the prevalence of quinolone-resistant strains of E. coli in stools on admission, and the characteristics of any nosocomial infections.

    Methods 

    Eighty-three consecutively hospitalized cirrhotic patients were included in this prospective study.

    The presence of quinolone-resistant strains of E. coli in stools on admission, and the characteristics of any nosocomial infections were recorded.

    Results 

    Fourteen out of 83 patients (16.8%) showed quinolone-resistant E. coli in stools (Group I), and 69 did not (Group II).

    Thirteen out of 14 from Group I (92.8%) and 17/69 (24.6) from Group II had received primary or secondary prophylaxis with norfloxacin (p<0.001).

    During hospitalization, 12/12 (100%) of patients from Group I and 25/66 (37.8%) of patients from Group II underwent norfloxacin prophylaxis.

    Three bacterial infections in patients from Group I, 3 from Group II patients receiving norfloxacin and 16 from Group II patients not receiving norfloxacin were recorded (p<0.05).

    No infections due to quinolone-resistant E. coli were observed in patients colonized with these bacteria.

    Treatment with norfloxacin induced the development of quinolone-resistant E. coli in 6/14 (42. (...)

    Mots-clés Pascal : Cirrhose, Foie, Chimioprophylaxie, Ascite, Antibactérien, Norfloxacine, Résistance traitement, Escherichia coli, Enterobacteriaceae, Bactérie, Infection nosocomiale, Epidémiologie, Homme, Appareil digestif pathologie, Foie pathologie, Abdomen pathologie, Epanchement

    Mots-clés Pascal anglais : Cirrhosis, Liver, Chemoprophylaxis, Ascites, Antibacterial agent, Norfloxacin, Negative therapeutic reaction, Escherichia coli, Enterobacteriaceae, Bacteria, Nosocomial infection, Epidemiology, Human, Digestive diseases, Hepatic disease, Abdominal disease, Effusion

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0451367

    Code Inist : 002B13C03. Création : 22/03/2000.